Atom Investors’s Nektar Therapeutics NKTR Stock Holding History

Atom Investors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.11M	Buy	+43,227	New	+$2.46M	0.22%	148

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Atom Investors's NKTR Position: Q1 2026 in Review

Atom Investors opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 43,227 shares worth $3.11M. The stake represents 0.22% of the portfolio and ranks #148 among its holdings.

215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Atom Investors held 43,227 shares of Nektar Therapeutics worth $3.11M as of Q1 2026.
Nektar Therapeutics was a new Atom Investors position in Q1 2026.
Nektar Therapeutics made up 0.22% of Atom Investors's portfolio in Q1 2026, its #148 holding.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.